Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » NantHealth Q2 Revenues Decline 12 Percent

NantHealth Q2 Revenues Decline 12 Percent

Aug 06, 2020
|
staff reporter

NEW YORK – NantHealth said Thursday after the close of the market that its second quarter revenues declined 12 percent to $17.6 million from $20.1 million in Q2 2019

The Culver City, California-based company had total software-related revenues of $17.5 million, down 4 percent from $18.3 million in Q2 2019. All software-related revenues now come from software-as-a-service (SaaS) offerings.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Another Protocol Released

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

From Just Some Blood

Time magazine looks into how liquid biopsies are changing cancer care.

Numerous Countries Agree to Vaccine Plan

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

PNAS Papers on Hypertrophic Cardiomyopathy, Major Depression, Spanish SARS-CoV-2 Cat

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.

What's Popular?

In Business News

  1. Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

    Premium

  2. Illumina to Acquire Grail for $8B in Cash and Stock

  3. Genosity Inks Comarketing Agreement with Personal Genome Diagnostics

  4. FDA Grants Emergency Use Authorization for GK Pharmaceuticals Coronavirus Test

  5. Biocept Lung Cancer Liquid Biopsy Test Obtains Coverage From Blue Cross Affiliate Highmark

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.